Pricing Log in Create free account

Dyadic International Inc. (DYAI) vs TScan Therapeutics, Inc. (TCRX)

Dyadic International Inc. and TScan Therapeutics, Inc. are both Biotechnology companies. Dyadic International Inc. and TScan Therapeutics, Inc. are of similar size ($16.8M and $16.2M). TScan Therapeutics, Inc. grew revenue faster over the last twelve months: 2.15% against −8.05%. Dyadic International Inc. has the higher net margin (−200.5% vs −1,655.4%) and the higher return on invested capital (0.00% vs −4,588.2%). Across the 17 metrics below, Dyadic International Inc. leads on 10 and TScan Therapeutics, Inc. on 7.

Valuation

Metric DYAI TCRX Biotechnology median
P/E n/m n/m 8.50
P/S 3.93 4.20 9.71
P/B n/m 0.43 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.32 0.64
EV/Sales 4.03 (5.27) 9.21
Earnings yield (56.10%) (395.65%) (33.15%)
Free cash flow yield (50.30%) (396.18%) (25.50%)

Profitability

Metric DYAI TCRX Biotechnology median
Gross margin 16.24% 100.00% 65.16%
Operating margin (195.47%) (1,695.15%) 0.00%
Net margin (200.46%) (1,655.35%) 0.00%
Free cash flow margin (194.73%) (1,665.18%) 0.00%
Return on equity 522.58% (95.80%) (56.36%)
Return on assets (103.88%) (50.09%) (48.04%)
Return on invested capital 0.00% (4,588.23%) 0.00%

Growth

Metric DYAI TCRX Biotechnology median
Revenue growth (TTM) (8.05%) 2.15% 6.02%
EPS growth (last fiscal year) (15.00%) 12.28% 30.26%
Revenue growth, 5-year CAGR 14.04% 56.92% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DYAI TCRX Biotechnology median
Debt to equity (2.11) 0.47 0.00
Current ratio 1.65 3.37 4.72
Net debt to EBITDA 0.49 0.90 0.96

Dividend

Metric DYAI TCRX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric DYAI TCRX Biotechnology median
Market cap 16.80m 16.21m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack